Prednisolone acetate

Lupin's leadership anticipates strong double-digit growth in FY25, with India's robust market and diabetes segment recovery. The US business focuses on new product launches and sustained profitability, targeting a core margin of 23-25%.

NMV/r (Paxlovid™) is an oral antiviral COVID-19 treatment authorized under EUA by the FDA, effective in reducing hospitalizations and deaths in high-risk patients. It inhibits SARS-CoV-2 Mpro, preventing viral replication, and is coadministered with ritonavir to enhance pharmacokinetics. Real-world studies show NMV/r's effectiveness in reducing severe COVID-19 progression. However, ritonavir's inhibition of CYP3A4 and other enzymes can lead to significant drug-drug interactions (DDIs), necessitating careful patient selection and management of concomitant medications. Pfizer's Global SDB reported 966 cases of DDIs, with low reporting rates (0.005%) and mostly nonserious events, though 33.2% of global cases and 22.7% of US cases were serious, including 1.4% and 1.0% with fatal outcomes, respectively.

TRS01 eye drops (dazdotuftide) show potential as a first-line treatment for non-infectious anterior uveitis (NIAU), offering a steroid-free option with a favorable safety profile, as presented at the 128th AAO Meeting. TRS01, a novel conjugate of anti-inflammatory molecules, demonstrated efficacy in reducing inflammation and ocular pain, with fewer IOP elevation risks compared to prednisolone.

Lupin launches first generic of Pred Forte (Prednisolone Acetate Ophthalmic Suspension) in the US, receiving 180-day CGT exclusivity.

Lupin Limited launched the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the U.S., receiving 180-day competitive generic therapy exclusivity. The drug treats steroid-responsive inflammation and had estimated annual sales of USD 198 million.